Strong topline growth masks battery losses; execution risk on capex delays
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Fluoropolymer beat 17–20% guidance with 22% delivery. Battery materials on track for 3-digit Q4 but currently loss-making. Capex target INR 3,100 Cr slipping due to Oman delay.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong topline growth (45.5% YoY revenue, 34.1% PAT) and fluoropolymer beat guidance (22% vs 17–20%), but battery materials losing ₹~50 Cr currently despite commercial ramp expected Q4 FY27. Capex execution risk: Oman project delayed 1–1.5 quarters, LFP capacity expansion pushed. Margin stable at 27% EBITDA but flat sequentially.
₹1760 Cr
Revenue · +45.5% YoY₹240 Cr
Reported PAT · +34.1% YoYFlat
Margins · vs guidance: CorroboratedDid the claims hold up?
Fluoropolymer 22% YoY growth, beat 17–20% guidance
METINR 931 Cr vs INR 764 Cr YoY (22% confirmed). Guidance reaffirmed at 17–20%, so beat on delivery.
Chemical segment PAT 46% YoY growth to INR 290 Cr
METConsolidated PAT INR 240 Cr; chemical segment INR 290 Cr implies battery segment loss ~INR 50 Cr. Claim checks against chemical segment, not consolidated.
EBITDA margin 27%, resilient despite market environment
METEBITDA INR 473 Cr on revenue INR 1,760 Cr = 26.9% OPM; call states 27% EBITDA margin. Consistent.
Battery materials ramp-up to 3-digit revenue by Q4 FY27
METLiPF6 sales to 5 major global electrolyte players, commercial supplies Q4 FY27. Currently in loss (INR ~50 Cr negative). On track, not yet realized.
R-32 utilization to reach full capacity by Q3 FY27
METMD: 'quarter going on, we'll probably reach the full utilization.' Fluorochemicals revenue up 135% YoY on R-32 demand. Directionally supported but not yet at full.
Capex on track: INR 3,100 Cr FY27 spend
OVERSTATEDMD disclosed Oman project delayed 1–1.5 quarters, LFP capacity expansion pushed, some delay to Q4 FY27 start. Spend overall tracking but slower than initially planned.
Earnings quality
What changed since the last call
Fluoropolymer delivery beats prior guidance
UpgradeQ2 delivered 22% YoY (INR 931 Cr) vs reaffirmed 17–20% guidance. Growth momentum accelerating in high-value applications (automotive FKM, PSA, data centers).
Battery segment still loss-making, not yet profitable
NeutralChemical segment PAT +46% YoY to INR 290 Cr, but battery segment ~INR 50 Cr loss. Expected; on track to 3-digit Q4 revenue per guidance.
Capex execution slips; Oman project delayed
DowngradeINR 2,100 Cr of ₹3,100 Cr battery capex now pushed 1–1.5 quarters. Project was planned to India but hold taken; LFP additional capacity also deferred.
Bulk Chemicals revenue down 5% YoY
DowngradeINR 151 Cr vs INR 158 Cr YoY (Q2 FY26), decline driven by caustic soda price collapse and higher captive consumption for R-32 production.
The Q&A
Analysts pressed hard on capex execution (Ankur, Akash, Archit on delays, funding, anode timing, cathode sourcing). MD candid about Oman delay 1–1.5Q, LFP capacity deferral, anode project 'not a priority right now'. On pricing (Sanjesh on LiPF6 China deflation), MD acknowledged lithium-linked drop but held margin defense. On volume binding (Hansal), disclosed multi-year contracts with volume binding, supporting long-term visibility. Overall, analysts held management to account; management held firm on guidance.
PTFE dry electrode adoption — Ketan Gandhi, Gandhi Securities
AnsweredPTFE grades advanced-stage commercial trial with multiple companies. MD: 'very optimistic,' demand for PTFE will pick up as battery OEMs move to dry electrode systems. Several grades in advanced trial, no solvent recovery/environmental upside.
Janiadara plant scope and capex — Ketan Gandhi, Gandhi Securities
DodgedMD declined to name specific chemicals (WF6, CaF6, NF3, F2, etc.). 'Very early stage of discussion, will share in next quarters.' Strong government push on sector, significant opportunity with fluorochemical expertise.
R-32 capacity utilization timeline — Sanjesh Jain, ICICI Securities
AnsweredMD: 'This quarter going on, we'll probably reach the full utilization.' R-134A production commences Q4 FY27. Capex on track for both.
LiPF6 pricing pressure and sustainability — Sanjesh Jain, ICICI Securities
AnsweredMD: 'Lithium price is −what LiPF6 is dropping as a result. Lithium pricing falloff.' Margin protected via lithium pass-through formula with customers. Adder-based pricing maintains spread.
LFP capacity expansion and timing — Sanjesh Jain, ICICI Securities
PartialMD: 'Next financial year, capacity and what we had planned, we'll see impact of that in next 2 to 3 quarters.' Ramp-up due to qualification, order pipeline strong. Expanded capacity + existing LiPF6 plant full swing by Q1 FY28.
Battery capex breakdown and execution — Ankur Periwal, Axis Capital
AnsweredINR 800 Cr for fluoropolymer/chemicals mostly done. INR 2,100 Cr battery: INR 900 Cr for LiPF6 on track, INR 1,200 Cr for salt/electrolyte/anode/backward integration. Oman capex on hold, capacity to India instead. Delays expected.
Anode project timeline and capex — Archit Joshi, Nuvama
DodgedMD: 'Anode will come subsequent to LFP. Right now, focus is LFP, electrolyte, salt.' Anode capex deferred; not a priority. May start late next FY depending on market. No specific timeline given.
Electrolyte demand ramp India — Archit Joshi, Nuvama
AnsweredMD: 'Middle of next financial year, we expect domestic market to slowly ramp up.' Electrolyte revenues likely mid-FY28 onwards. Current battery production in India 'very, very low' on gigawatt hour basis.
FY28 battery revenue scale and composition — Rohit Nagraj, 360 ONE Capital
PartialMD: 'Initially, a big part of revenue will come from salt. LFP larger capacity towards Q3. Then electrolyte.' FY28 ramp tied to capacity commissioning. Exports first, domestic slow ramp middle of FY28.
LiPF6 customer volume binding — Hansal Thacker, Lalkar Securities
AnsweredRajiv Rao: 'Annual contracts or longer. Volume bound for at least next financial year, some longer.' Long-term contracts with major electrolyte players. Limited spot exposure.
Guidance
Fluoropolymer 17–20% annual growth (reaffirmed)
HighQ2 delivered 22%, exceeding range. Management confident in sustained high-value application traction.
Battery materials 3-digit revenue by Q4 FY27
MediumLiPF6 sales ramping, PVDF/PTFE in qualification. Timing tied to customer approvals and capex execution.
EBITDA margin ~27% (reaffirmed)
HighResilience demonstrated in Q2; margin protected despite input cost volatility (lithium pass-through, caustic soda deflation).
FY27 capex INR 3,100 Cr (INR 2,300 Cr battery/EV, INR 800 Cr chemicals)
MediumOn track but slipping. Oman project delayed 1–1.5 quarters; capacity shifted to India. LFP expansion deferred. Expected to slip into FY28.
Multi-year capex target INR 6,000 Cr over next few years
LowAspirational; tied to battery commercialization pace and approval timelines. No specific horizon given.
Risks the call surfaced
Capex execution delay
HighOman LFP project on hold, shifted to India; 1–1.5 quarter delay. LFP expansion timeline pushed back. Execution risk on multi-year INR 6,000 Cr capex plan.
Battery segment profitability timeline
HighBattery segment currently loss-making (~INR 50 Cr in Q2). Profitability depends on customer qualification timelines, electrolyte demand ramp in India (expected mid-FY28), and volume scale. Execution heavily dependent on OEM approvals.
LiPF6 pricing pressure from China
MediumLiPF6 prices down 33% in one month (INR 150K → INR 100K/unit) due to Chinese competition. Margin protected via lithium pass-through, but tail risk if volumes don't scale or lithium prices stabilize while competitive pressure persists.
Domestic battery demand uncertainty
MediumElectrolyte ramp in India expected mid-FY28, not FY27. Current battery production in India 'very, very low' on gigawatt-hour basis. Timing of domestic EV/battery adoption uncertain; affects ramp-up pace and capex utilization.
Bulk Chemicals margin pressure
LowBulk Chemicals down 5% YoY to INR 151 Cr. Caustic soda price collapse driving decline; higher captive R-32 consumption reducing available volumes for external sale. Margin dependent on R-32 ramp and caustic soda price recovery.
Management
Score 7/10. Clear and transparent. MD provided detailed segment-wise breakdowns, acknowledged capex delays (Oman), explained pricing dynamics (lithium pass-through). Some deflection on Janiadara chemicals and anode project timing, citing early-stage discussions. Mixed. Fluoropolymer beat 17–20% guidance (22% delivered). Battery materials on track for Q4 3-digit revenue but currently loss-making. Capex slipped: Oman delayed 1–1.5 quarters. EBITDA margin at 27% is solid.
1 · Q3 FY27 (Oct–Dec 2026)
R-32 utilization at full capacity; R-134A production commences
2 · Q4 FY27 (Jan–Mar 2027)
Battery materials 3-digit revenue realization; LiPF6 commercial supplies begin
3 · H2 FY28 (Jul 2027+)
Domestic electrolyte demand ramp-up; LFP larger capacity utilization begins
Margin stable at 27% EBITDA but flat sequentially.
Informational and educational content only. Not investment advice.